• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    9/29/25 6:51:36 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTA alert in real time by email
    8-K
    ENANTA PHARMACEUTICALS INC false 0001177648 0001177648 2025-09-29 2025-09-29
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 29, 2025

     

     

    ENANTA PHARMACEUTICALS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware
      001-35839
      04-3205099
    (State or Other Jurisdiction
    of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

    4 Kingsbury Avenue

    Watertown, Massachusetts

        02472
    (Address of Principal Executive Offices)     (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (617) 607-0800

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $0.01 per share   ENTA   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 7.01

    Regulation FD Disclosure.

    On September 29, 2025, Enanta Pharmaceuticals, Inc. (“Enanta”) issued a press release announcing positive topline data from its Phase 2b high-risk adults study of zelicapavir (formerly EDP-938) for the treatment of respiratory syncytial virus (“RSV”). A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by this reference.

    The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

     

    Item 8.01

    Other Events.

    As noted in Item 7.01 above, Enanta announced positive topline data from its Phase 2b high-risk adults study of zelicapavir for the treatment of RSV on September 29, 2025.

    This Phase 2b study was a randomized, double-blind, placebo-controlled study of RSV infection in non-hospitalized adults who are at high risk of complications, including the elderly and/or those with congestive heart failure (“CHF”), chronic obstructive pulmonary disease (“COPD”) or asthma. The proportion of patients aged 65-74 years or those with asthma was capped at 20% of the total population. Patients were enrolled within 72 hours of symptom onset and received 800mg of zelicapavir or placebo once daily for 5 days. The goal of this proof-of-concept, signal finding study was to inform the design of a Phase 3 trial, including populations and endpoints, as well as give an indication of a treatment effect on symptoms that could be confirmed in a larger registrational study. Symptoms were measured using the Respiratory Infection Intensity and Impact Questionnaire (“RiiQTM”) scale, which evaluates a total of 29 parameters, including 13 RSV symptoms, four of which are lower respiratory tract disease (“LRTD”) symptoms, and three other impact of disease components (daily activities, emotions, and social relationships). The primary endpoint evaluated the time to resolution of the LRTD subset of four symptoms to mild. Predefined analyses of complete resolution, defined by all symptoms absent, were also conducted. Multiple secondary endpoints, including all 13 RSV symptoms, total RiiQTM score, additional patient reported outcomes (e.g.; PGI-S), virology, safety, and hospitalization rate, were assessed.

    A total of 186 subjects received 800mg of zelicapavir (n=121) or placebo (n=65) orally, once daily for 5 days and were evaluated for 28 days thereafter (safety population). An efficacy population of 175 patients was further defined as those who were PCR positive for RSV at a central laboratory. An HR3 population was defined as those who had CHF, COPD, or age >75 (81% of the efficacy population). Demographics and baseline characteristics were balanced across treatment groups, with the majority of patients being enrolled within 48 hours of symptom onset.

    Zelicapavir demonstrated a favorable safety profile over the initial 5-day dosing period and through 28 days of follow-up, with adverse events (“AEs”) being similar between zelicapavir and placebo. No adverse events led to treatment discontinuation or study withdrawal in the zelicapavir group. The majority of AEs were mild with diarrhea and asthma being the most common AEs on zelicapavir at 3.3% and 2.5%, respectively.


    A clinically meaningful improvement in time to complete resolution (defined as all symptoms absent) of all 13 RSV symptoms and in the total RiiQTM was observed for zelicapavir compared to placebo in both the efficacy and HR3 populations. There was also a faster time to complete resolution of the subset of four LRTD symptoms in the HR3 population.

     

         LRTD
    4 Symptoms
       All RSV
    13 Symptoms
       Total RiiQ™
    All 29 Parameters

    Efficacy Population

       0.5 days    2.2 days    3.6 days

    HR3 Population

       3.0 days    6.7 days    7.2 days

    No effect was observed on the time to resolution of symptoms (defined as mild), including the primary endpoint of time to resolution of the LRTD subset of four symptoms in the efficacy population.

    Additionally, a statistically significant improvement in RiiQTM RSV 13-symptom score in the HR3 population at Days 9 (p=0.0403) and 14 (p=0.0247) was observed in a post-hoc analysis for zelicapavir compared to placebo.

    Furthermore, the study met a key secondary endpoint with zelicapavir treatment resulting in a statistically significant 2-day faster improvement in a Patient Global Impression of Severity (“PGI-S”) score compared to placebo in both the efficacy population (p=0.0446) and the HR3 population (p=0.0465).

    Importantly, a lower hospitalization rate was observed for patients treated with zelicapavir (1.7%) compared to placebo (5.0%). Blinded attribution by investigators judged none (0%) of the hospitalizations on zelicapavir and all (5.0%) of the hospitalization on placebo to be related to RSV. Post-hoc attribution suggested RSV-relatedness of 0.9% for the patients on zelicapavir compared to 5.0% on placebo.

    The study met key secondary virology endpoints showing a robust antiviral effect, with a statistically significantly greater proportion of zelicapavir patients having an undetectable viral load at the end of treatment compared with placebo. In the efficacy population undetectable viral load at the end of treatment was 23.5% vs 10.0% in placebo (p=0.0198), and in the HR3 population was 23.9% vs 10.0% in placebo (p=0.0292). Treatment with zelicapavir resulted in a 4- or 5-day faster median time to undetectable viral load and a 0.6 or 0.7 log decline in viral load at the end of treatment compared to placebo for the efficacy and HR3 populations, respectively.

    Forward Looking Statements

    This Current Report on Form 8-K includes forward-looking statements, including with respect to the prospects for further development and advancement of zelicapavir for the treatment of RSV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this report are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the development risks of early stage discovery efforts in the disease areas in Enanta’s research and development pipeline, such as RSV; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV; Enanta’s limited clinical development experience; Enanta’s need to attract and retain senior management and key scientific personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this report. All forward-looking statements contained in this report speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    Number

      

    Exhibit Description

    99.1    Press release dated September 29, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 29, 2025   ENANTA PHARMACEUTICALS, INC.
        By:  

    /s/ Jay R. Luly, Ph.D.

          Jay R. Luly, Ph.D.
          President and Chief Executive Officer
    Get the next $ENTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENTA

    DatePrice TargetRatingAnalyst
    7/28/2025$20.00Buy
    H.C. Wainwright
    8/9/2023$14.00Neutral → Underweight
    JP Morgan
    8/8/2023$49.00 → $18.00Buy → Hold
    Jefferies
    12/9/2022$56.00Buy
    H.C. Wainwright
    7/6/2022$62.00In-line → Outperform
    Evercore ISI
    6/1/2022$39.00Underperform → In-line
    Evercore ISI
    2/9/2022$80.00 → $68.00Market Perform
    SVB Leerink
    1/13/2022$85.00 → $80.00Market Perform
    SVB Leerink
    More analyst ratings

    $ENTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are being offered by Enanta. The offering is expected to close on October 2, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds to Enanta from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $65.0 million. In addition, Enanta has granted the underwri

    9/30/25 9:00:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta intends to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be compl

    9/30/25 4:11:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 Statistically Significant Improvement in Patient Global Impression of Severity Score Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%) 4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo Management to Host Conference Call and Webcast Today at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases,

    9/29/25 6:30:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    SEC Filings

    View All

    SEC Form 424B5 filed by Enanta Pharmaceuticals Inc.

    424B5 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/30/25 4:43:53 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/29/25 8:20:18 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

    9/29/25 6:51:36 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Luly Jay R. bought $256,050 worth of shares (45,000 units at $5.69), increasing direct ownership by 6% to 846,638 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    2/12/25 8:09:35 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Enanta Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    7/28/25 8:57:53 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals downgraded by JP Morgan with a new price target

    JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00

    8/9/23 7:32:28 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals downgraded by Jefferies with a new price target

    Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously

    8/8/23 6:35:35 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Capps Kathleen S. claimed ownership of 5,829 shares (SEC Form 3)

    3 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    9/8/25 6:01:31 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Trout Harry R. Iii claimed ownership of 10,912 shares (SEC Form 3)

    3 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    9/8/25 6:00:59 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rottinghaus Scott T. covered exercise/tax liability with 2,217 shares, decreasing direct ownership by 9% to 22,590 units (SEC Form 4)

    4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

    8/8/25 4:35:45 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Financials

    Live finance-specific insights

    View All

    Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75 Statistically Significant Improvement in Patient Global Impression of Severity Score Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%) 4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo Management to Host Conference Call and Webcast Today at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases,

    9/29/25 6:30:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

    Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults. Conference Call and Webcast Information The live webcast can be accessed at "Events & Presentations" in the investors section of Enanta's website. To participate by phone

    9/26/25 4:01:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

    On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September On Track to Select a STAT6 Development Candidate in 2H 2025 Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor Candidate, in Development for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell Driven Diseases Operations Supported by Cash and Marketable Securities Totaling $204.1 Million at June 30, 2025, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and i

    8/11/25 4:02:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Leadership Updates

    Live Leadership Updates

    View All

    Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

    4/30/24 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

    8/8/22 4:00:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

    WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

    1/26/21 7:00:00 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    11/14/24 4:03:02 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    10/17/24 4:31:00 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)

    SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

    2/14/24 2:26:49 PM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care